KR20220125272A - 트리사이클릭 테트라하이드로이소퀴놀린 유도체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도 - Google Patents
트리사이클릭 테트라하이드로이소퀴놀린 유도체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도 Download PDFInfo
- Publication number
- KR20220125272A KR20220125272A KR1020227026103A KR20227026103A KR20220125272A KR 20220125272 A KR20220125272 A KR 20220125272A KR 1020227026103 A KR1020227026103 A KR 1020227026103A KR 20227026103 A KR20227026103 A KR 20227026103A KR 20220125272 A KR20220125272 A KR 20220125272A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- cycloalkyl
- group
- heterocyclyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010025118 | 2020-01-10 | ||
| CN202010025118.5 | 2020-01-10 | ||
| CN202010036802.3 | 2020-01-14 | ||
| CN202010036802 | 2020-01-14 | ||
| CN202010273891 | 2020-04-09 | ||
| CN202010273891.3 | 2020-04-09 | ||
| CN202010680491.4 | 2020-07-15 | ||
| CN202010680491 | 2020-07-15 | ||
| CN202010819555.4 | 2020-08-14 | ||
| CN202010819555 | 2020-08-14 | ||
| CN202010971693 | 2020-09-16 | ||
| CN202010971693.4 | 2020-09-16 | ||
| PCT/CN2021/070826 WO2021139756A1 (zh) | 2020-01-10 | 2021-01-08 | 三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220125272A true KR20220125272A (ko) | 2022-09-14 |
Family
ID=76787742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227026103A Pending KR20220125272A (ko) | 2020-01-10 | 2021-01-08 | 트리사이클릭 테트라하이드로이소퀴놀린 유도체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12428428B2 (enExample) |
| EP (1) | EP4089094A4 (enExample) |
| JP (1) | JP7657807B2 (enExample) |
| KR (1) | KR20220125272A (enExample) |
| CN (2) | CN114746424B (enExample) |
| AU (1) | AU2021205156B2 (enExample) |
| BR (1) | BR112022013322A2 (enExample) |
| CA (1) | CA3164166A1 (enExample) |
| MX (1) | MX2022008091A (enExample) |
| TW (1) | TWI882060B (enExample) |
| WO (1) | WO2021139756A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021205156B2 (en) | 2020-01-10 | 2026-07-02 | Jiangsu Hengrui Medicine Co., Ltd. | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine |
| CN117642405B (zh) * | 2021-07-09 | 2026-05-12 | 江苏恒瑞医药股份有限公司 | 一种三环四氢异喹啉类衍生物的盐型 |
| CN117813288A (zh) | 2021-07-15 | 2024-04-02 | 西藏海思科制药有限公司 | 芳氨基衍生物雌激素受体调节剂及其用途 |
| JP2025529974A (ja) | 2022-09-09 | 2025-09-09 | サノフイ | 置換テトラヒドロシクロヘプタ[e]インドール誘導体、それらの調製のプロセス及びその治療的使用 |
| WO2025209455A1 (zh) * | 2024-04-01 | 2025-10-09 | 山东盛迪医药有限公司 | 一种选择性雌激素受体降解剂的制备方法 |
| WO2026086864A1 (zh) * | 2024-10-24 | 2026-04-30 | 江苏恒瑞医药股份有限公司 | 一种kat6抑制剂的联合使用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1113007A1 (en) | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| RU2009122670A (ru) | 2006-12-21 | 2011-01-27 | Плекссикон, Инк. (Us) | Соединения и способы для модуляции киназ и показания к их применению |
| WO2013073875A1 (ko) | 2011-11-15 | 2013-05-23 | 한국화학연구원 | 신규한 항바이러스성 피롤로피리딘 유도체 및 이의 제조방법 |
| EP2941421A4 (en) | 2013-01-07 | 2016-09-21 | Bg Negev Technologies & Applic Ltd | COUMESTAN, COUMESTROL, COUMESTAN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF |
| WO2014141292A2 (en) | 2013-03-04 | 2014-09-18 | Intas Pharmaceuticals Limited | Endoxifen citrate polymorph and process for preparing the same |
| IN2013MU00665A (enExample) | 2013-03-05 | 2015-07-03 | Cipla Ltd | |
| CN105121413B (zh) | 2013-03-14 | 2018-09-14 | 赛拉根医药股份有限公司 | 多环雌激素受体调节剂及其用途 |
| EP2981530B1 (en) | 2013-04-04 | 2020-02-12 | The Administrators of the Tulane Educational Fund | Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells |
| AP2015008858A0 (en) | 2013-05-28 | 2015-11-30 | Astrazeneca Ab | Chemical compounds |
| WO2015092634A1 (en) * | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| EP3312184A4 (en) * | 2015-06-16 | 2019-02-27 | Jiangsu Hengrui Medicine Co., Ltd. | PIPERIDINE DERIVATIVE AND ITS PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF |
| EP3328999B1 (en) | 2015-07-30 | 2020-03-25 | Arcis Biotechnology Holdings Limited | Method using a quaternary ammonium compound |
| EP3440067B1 (en) * | 2016-04-08 | 2021-05-26 | F. Hoffmann-La Roche AG | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| UA125824C2 (uk) | 2016-10-24 | 2022-06-15 | Астразенека Аб | 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ |
| WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
| WO2019002442A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| CA3082276C (en) * | 2017-11-14 | 2022-08-16 | Anlin Pharmaceuticals, Llc | Heterocyclic compounds and their application in medicine |
| CN111770924B (zh) * | 2018-04-04 | 2023-05-09 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
| WO2019228443A1 (en) | 2018-05-30 | 2019-12-05 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Selective estrogen receptor downregulators and uses thereof |
| AU2021205156B2 (en) | 2020-01-10 | 2026-07-02 | Jiangsu Hengrui Medicine Co., Ltd. | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine |
-
2021
- 2021-01-08 AU AU2021205156A patent/AU2021205156B2/en active Active
- 2021-01-08 TW TW110100844A patent/TWI882060B/zh active
- 2021-01-08 CA CA3164166A patent/CA3164166A1/en active Pending
- 2021-01-08 JP JP2022540980A patent/JP7657807B2/ja active Active
- 2021-01-08 CN CN202180006879.9A patent/CN114746424B/zh active Active
- 2021-01-08 BR BR112022013322A patent/BR112022013322A2/pt unknown
- 2021-01-08 WO PCT/CN2021/070826 patent/WO2021139756A1/zh not_active Ceased
- 2021-01-08 KR KR1020227026103A patent/KR20220125272A/ko active Pending
- 2021-01-08 US US17/790,110 patent/US12428428B2/en active Active
- 2021-01-08 EP EP21738824.8A patent/EP4089094A4/en active Pending
- 2021-01-08 CN CN202310574384.7A patent/CN116731064B/zh active Active
- 2021-01-08 MX MX2022008091A patent/MX2022008091A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230140679A1 (en) | 2023-05-04 |
| CN114746424B (zh) | 2023-06-16 |
| AU2021205156A1 (en) | 2022-07-14 |
| CN114746424A (zh) | 2022-07-12 |
| BR112022013322A2 (pt) | 2022-09-20 |
| JP2023509944A (ja) | 2023-03-10 |
| US12428428B2 (en) | 2025-09-30 |
| TW202140495A (zh) | 2021-11-01 |
| CN116731064A (zh) | 2023-09-12 |
| TWI882060B (zh) | 2025-05-01 |
| EP4089094A1 (en) | 2022-11-16 |
| AU2021205156B2 (en) | 2026-07-02 |
| CN116731064B (zh) | 2026-06-16 |
| CA3164166A1 (en) | 2021-07-15 |
| WO2021139756A1 (zh) | 2021-07-15 |
| EP4089094A4 (en) | 2023-08-02 |
| JP7657807B2 (ja) | 2025-04-07 |
| MX2022008091A (es) | 2022-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7813970B2 (ja) | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 | |
| JP7657807B2 (ja) | 三環式テトラヒドロイソキノリン誘導体、その調製方法及びその医薬的応用 | |
| CN109311876B (zh) | 杂芳基雌激素受体调节剂及其用途 | |
| CN109219604B (zh) | 四氢异喹啉雌激素受体调节剂及其用途 | |
| KR20230023672A (ko) | 피리딘-피리미딘 유도체, 이의 제조 방법 및 이의 약학적 용도 | |
| KR20180012853A (ko) | 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도 | |
| JP7720906B2 (ja) | ピロリジン化合物及びその使用 | |
| WO2024088343A1 (zh) | 一种芳基杂环类Kv1.3抑制剂及其制备方法和用途 | |
| CN111499614A (zh) | 四氢异喹啉类衍生物、其制备方法及其在医药上的应用 | |
| CN113874367B (zh) | 吲唑类衍生物、其制备方法及其在医药上的应用 | |
| RU2830109C1 (ru) | Трициклическое тетрагидроизохинолиновое производное, способ его получения и его применение в медицине | |
| KR20260020383A (ko) | Egfr 키나제의 분해를 위한 화합물 | |
| HK40076301A (en) | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine | |
| HK40076301B (en) | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine | |
| HK40064838A (en) | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | |
| WO2025161144A1 (zh) | 芳基杂环类Kv1.3抑制剂及其制备方法和用途 | |
| HK40064838B (en) | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | |
| HK40003989A (en) | Heteroaryl estrogen receptor modulators and uses thereof | |
| HK40003989B (en) | Heteroaryl estrogen receptor modulators and uses thereof | |
| HK1243074A1 (zh) | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |